Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab

Fig. 2

Change in tumor burden and circulating biomarkers after atezolizumab exposures. Changes in sum of lesion diameter (SLD) was assessed over time in initial (a) and second (b) exposure to atezolizumab. Plasma tumor antigens CEA and CA27–29 (c), circulating T, B and NK lymphocytes (d) and the cytokines IL18, CXCL10 and granzyme A (GZMA)) (e) were assessed over time during the first exposure to atezolizumab. Upper limit of normal levels for CEA (3 ng/ml) and CA27–29 (38 U/ml) are indicated by the dotted lines (blue: CA27-29; red: CEA). Changes in lymphocyte populations were plotted as ratio to baseline to pre-treatment values

Back to article page